TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: IU Health Krannert Personalized Medicine Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ischemic heart disease, who are prescribed dual antiplatelet therapy after percutaneous coronary intervention (PCI). Enrollment has to occur during index hospitalization or during outpatient visit for cath lab procedure.~Exclusion Criteria:~* Pregnant or breastfeeding.~* Unwilling or unable, in the opinion of the investigator, to comply with instructions on prescribed medicines.~* Prior known allergy or intolerance to clopidogrel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pharmacogenetic Results Available to Provider (Type: ACTIVE_COMPARATOR): Genotyping for CYP2C19 variants is performed. The test results are integrated into the electronic health record and alerts are displayed to the prescriber. The ultimate decision regarding antiplatelet therapy is left to the prescriber
- Control Arm (Type: NO_INTERVENTION): No genotyping information is performed as part of clinical care. Standard therapy is followed. Genotyping will be performed at conclusion of study in control arm, and genotyping results will not be incorporated into electronic health record.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed stage IIIB non-small cell lung cancer~  * Adenocarcinoma~ * Large cell carcinoma~ * Squamous cell carcinoma~* Pathologically or radiographically documented positive N3 nodes~  * No positive supraclavicular or scalene lymph nodes with disease extending into the cervical region OR~* T4 tumor invading any of the following:~  * Mediastinum~ * Heart~ * Great vessels~ * Trachea~ * Esophagus~ * Vertebral body~ * Carina~* No brain, contralateral chest, liver, or adrenal metastases~* No more than 1 parenchymal lesion~* No malignant pleural effusions unless they are only visible on CT scan or deemed too small to tap~* No pericardial effusions~* Measurable disease~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Zubrod 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Not specified~Renal:~* Creatinine clearance at least 50 mL/min~Pulmonary:~* One of the following:~  * FEV1 at least 2.0 L~ * Predicted FEV1 of contralateral lung greater than 800 mL~ * Predicted post-treatment FEV1 at least 1.0 L~Other:~* No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent growth factors during induction chemoradiotherapy~Chemotherapy:~* No prior chemotherapy for lung cancer~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy for lung cancer~Surgery:~* No prior surgical resection of lung cancer~* Prior exploratory thoracotomy, mediastinoscopy, excisional biopsy, or similar surgery for determining diagnosis, stage, or potential resectability allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chemo/RT followed by consolidation chemo (Type: EXPERIMENTAL): cisplatin docetaxel radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed and dated informed consent form (ICF)~2. Male or female, aged 20 to 80 years inclusive at the time of signing ICF~3. French-speaking~4. reliable informant~   Controls:~5. derived from the general population and consenting to participate in the study~   Patients:~6. MMS\>18~7. Patients followed for mild or major neurocognitive disorder related to :~   * Alzheimer's disease~  * Frontotemporal lobar degeneration~  * Lewy bodies disease~  * Parkinson's disease~  * Huntington's disease~  * Progressive supranuclear palsy~  * traumatic brain injury~  * stroke or cerebral anoxia~  * mixed diseases~  * focal cerebral diseases~Exclusion Criteria:~1. Illiteracy~2. mental retardation~3. visual or motor deficit preventing reading, drawing or writing (scores on the reading, drawing or sentence writing subtests of the MMSE = 0)~4. hearing impairment interfering with understanding of instructions,~5. history of brain disease, including head injury with loss of consciousness lasting \> 15 minutes, stroke, coma or loss of consciousness lasting \> 15 minutes, followed for sclerosis or other brain disease, brain radiation therapy, epilepsy currently requiring treatment~6. history of psychiatric illness (schizophrenia or other psychosis) or ongoing psychiatric illness (major depressive disorder or other condition) currently requiring treatment or requiring a stay \> 2 days in a psychiatry unit or anxiety requiring more than one medication at the present time~7. alcoholism (mean alcohol consumption \> 3 standard drinks/day or history of alcohol withdrawal)~8. use of opiates or other illicit drugs during the previous 3 months or causing withdrawal syndrome~9. ongoing antidepressant or antiepileptic treatment~10. anxiolytic or hypnotic treatment initiated or increased during the previous month~11. general anaesthesia during the previous 3 months~12. history of heart surgery with cardiopulmonary bypass~13. comorbidities affecting cognition (respiratory, renal, liver, heart failure...)~14. women of childbearing potential (defined as pre-menopausal, less than 2 years postmenopausal, or not surgically sterile)~15. persons placed under judicial protection~    Patients :~16. contraindication to MRI~    Controls:~17. deficit on MMSE \<27

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Patients (Type: ACTIVE_COMPARATOR): battery of tests of social cognition
- Control (Type: ACTIVE_COMPARATOR): battery of tests of social cognition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Denosumab in Primary Hyperparathyroidism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed hypercalcemic PHPT in postmenopausal women with serum calcium \>10.2 mg/dL and \< 12.0 mg/dL (nl: 8.6-10.2)~* T-score between -1.5 and -2.5 at any site. If the T-score is \<-2.5, patients become candidates for parathyroid surgery. They will be enrolled only if they refuse the parathyroid surgery~Exclusion Criteria:~* 25-hydroxyvitamin D level \< 20 ng/ml~* Previous use of the bisphosphonate zoledronic acid (ever), alendronate or risedronate (within 12 months) or ibandronate (within 6 months)~* Current use of PTH, glucocorticoids, SERMS, estrogen (other than vaginal), calcitonin or pharmacological amounts of calcitriol Current or previous use of cinacalcet (within 6 months)~* Hyperthyroidism~* Rheumatoid arthritis or any other inflammatory joint disease~* Paget's disease of bone~* Malabsorption~* T-score \<-3.5 at any site~* Signs of symptomatic PHPT (e.g, kidney stones within the past 5 years; fragility fracture within the past 2 years)~* Physical or mental handicapping condition that precludes ability to complete the protocol and/or provide informed consent.~* Subjects on Antiviral HIV therapy or subjects with compromised immune systems~* Premenopausal women or men~* Stage 5 Chronic Kidney Disease (CKD) or anyone on dialysis~* Creatinine clearance \< 30 cc/min unless the patient is not a candidate for surgery or if the patient refuses surgery

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab - Group #1 (Type: EXPERIMENTAL): Receive active drug for year 1 and year 2 of the study
- Placebo - Group #2 (Type: PLACEBO_COMPARATOR): Receive placebo for year 1 and active drug for year 2 of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prednisolone Addition for Patients With Recent-onset Psychotic Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A DSM-IV-R diagnosis of: 295.x (schizophrenia, schizophreniform disorder, or schizoaffective disorder) or 298.9 (psychosis NOS)~2. Onset of psychosis no longer than 7 years ago~3. Minimum total PANSS score of 60~4. Age 18 -70 years~5. Patients are treated with antipsychotic medication~6. Written informed consent is obtained~7. Female patients of childbearing potential need to utilize a proper method of contraception (the pill, vaginal ring, hormonal patch, intrauterine device, cervical cap, condom, contraceptive injection, diaphragm) in case of sexual intercourse during the study.~Exclusion Criteria:~1. Presence of any of the contra-indications of prednisolone as reported in the SPC.~2. Presence of diabetes mellitus or random (non-fasting) glucose levels exceeding 11 mmol/L at screening, severe heart failure, severe osteoporosis or systemic fungal infections.~3. Body Mass Index (BMI) of \>30.0~4. Current or chronic use of systemic glucocorticosteroids (temporary use is permitted, if stopped 1 month before start of treatment trial)~5. Chronic use of non-steroidal anti-inflammatory drugs, defined as daily use during more than 2 months. Intermittent use is permitted, if stopped at least 1 month before start of treatment trial.~6. Pregnancy or breast-feeding. A urine pregnancy test will be performed at screening.~7. Concurrent use of certain types of medication:~1. liver enzyme inducing medication such as carbamazepine, riphampicine, primidone, barbiturates and phenytoine~2. HAART medication (both HIV protease inhibitors and (non)-nucleoside reverse transcriptase inhibitors), especially efavirenz, ritonavir and lopinavir.~3. telaprevir and boceprevir in treatment of Hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Prednisolone (Type: EXPERIMENTAL): Prednisolone will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following treatment guidelines for Inflammatory Bowel Diseases (2008).
- Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): Placebo will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following the treatment schedule of the experimental arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
During the Phase 1 and Phase 2 portions of the study, participant eligibility criteria are identical except for prior treatment for anaplastic thyroid cancer (ATC). During Phase 1, eligible participants may have received prior chemotherapy while during Phase 2, eligible participants must be chemotherapy naïve.~Inclusion Criteria:~* Histologically or cytologically diagnosed, advanced ATC~* Measurable lesion(s)~* Lesion(s) (primary or metastatic) with viable tumor tissue accessible for repeated biopsy~* Age equal to or older than 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2~* Adequate organ and bone marrow function~* Agreement to use effective contraception while on treatment and for equal to or greater than 3 months after end of treatment~* Pregnant or breastfeeding~Exclusion Criteria:~* Medical history of diabetes mellitus requiring treatment with insulin or oral agents; no pleural or pericardial effusion or clinically significant pulmonary or cardiovascular disease.~* Clinically active brain metastasis, uncontrolled seizure disorder, spinal cord compression, or carcinomatous meningitis~* Clinically significant active infection requiring antibiotic or antiretroviral therapy~* Concomitant use of other thiazolidinediones (TZDs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1; 0.15 mg CS-7017 (Type: EXPERIMENTAL): Participants who received 0.15 mg twice daily (BID) oral CS-7017 and 135 \[Dose Level 1a\] or 175 \[Dose Level 1b\] mg/m\^2 intravenous (IV) paclitaxel once every 3 weeks.
- Cohort 2; 0.30 mg CS-7017 (Type: EXPERIMENTAL): Participants who received 0.30 mg twice daily (BID) oral CS-7017 and 175 mg/m\^2 IV paclitaxel once every 3 weeks.
- Cohort 3; 0.50 mg CS-7017 (Type: EXPERIMENTAL): Participants who received 0.50 mg twice daily (BID) oral CS-7017 and 175 mg/m\^2 IV paclitaxel once every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male or female, ages between 8 and 17~* Body Mass Index \> 30~* fasting blood sugar between 90-100 mg/dl~* 2 hour post prandial \>140 \<180 mg/dl~* meets criteria for a diagnosis of ADHD, any subtype~Exclusion Criteria:~* known cardiovascular disease or diabetes~* structural cardiac abnormalities, abnormal ECGs, family history of sudden death~* positive urine drug screen~* fasting blood sugar level \> 126 mg/dl~* HbA1c \> 6.5 %~* Weight \> 300 lbs

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Open label Vyvanse (Type: ACTIVE_COMPARATOR): Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of PVI Plus Catheter Ablation or PVI Alone for the Treatment of AFib for Patients With Paroxysmal Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~(Step 1 - Registration)~* The subject is 18 years of age or older~* Left atrium \< 6.0 cm (Trans Thoracic Echo - TTE - parasternal 4 chamber view~* performed within 6 months)~* Documentation of AF that terminates spontaneously or with intervention within 7 days of onset (PAF) Failed or refractory to one AAD (class I and/or III)~* Provided written informed consent~* Be eligible for an AF ablation procedure for Paroxysmal AF~(Step 2 - Randomization)~* Sustained AF following PVI with ability to receive additional linear or focal intracardiac catheter ablation~Exclusion Criteria:~(Step 1 - Registration)~* Pregnant or planning to become pregnant during study~* Co-morbid medical conditions that limit one-year life expectancy~* Previous cardiac surgery~* Patients who have active infection or sepsis~* Patients with esophageal ulcers strictures and varices~* Patients who are contraindicated for anticoagulants such as heparin and warfarin~* Patients who are being treated for ventricular arrhythmias~* Patients who have had a previous left atrial catheter ablation for AF (does not~* include ablation for AFL or other supraventricular arrhythmias)~* Current participation in another clinical investigation of a medical device or a drug, or recent participation in such a study within 30 days prior to study enrollment~* Not competent to legally represent him or herself (e.g., requires a guardian or~* caretaker as a legal representative)~(Step 2 Randomization)~* Not able to receive additional linear or focal intracardiac catheter ablation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PVI Plus Catheter Ablation (Type: ACTIVE_COMPARATOR): Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
- PVI Alone (Type: ACTIVE_COMPARATOR): Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Urinary KIM-1 After Vancomycin or Linezolid Administration

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Eligible patients are male or female adults ≥18 years of age with an expected hospital stay of at least 48 hours.~* Eligible patients are already prescribed intravenous vancomycin or linezolid per their primary care providers as a standard of care and dosed in manner that is consistent with current institutional practices. Receipt of these antibiotics is not investigational.~Exclusion Criteria:~* Exclusion criteria will include patients who have stage 3or greater Chronic Kidney Disease or who have acute kidney injury prior to the start of intravenous vancomycin therapy, patients that only receive one dose of IV vancomycin or linezolid in total, as well as patients with potentially altered pharmacokinetic parameters (pregnant patients, burn patients, and those that are morbidly obese (BMI ≥ 40 kg/m2).~* Additionally, patients will be excluded if they are to receive more than 1 concurrent nephrotoxic medication within the prior 72 hours, have received intravenous contrast within 120 hours before randomization, exhibit baseline hematuria, or baseline proteinuria.~* A list of concurrent nephrotoxins that would exclude patients from the study is provided in Appendix C.~* Age Range: ≥18 years of age, if age \> 90 will report as \> 90 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vancomycin (Type: None): Vancomycin
- Linezolid (Type: None): Linezolid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Select Inclusion Criteria:~* Male or female patients ≥ 18 years of age with a confirmed diagnosis of Ph+ CML-CP and CCyR~* A suboptimal molecular response to imatinib defined as:~  * Group 1: Treated with 1 year of imatinib, complete cytogenetic response (CCyR) but no major molecular response (MMR) (Bcr-Abl levels \>0.1%IS);~ * Group 2: No specific duration of imatinib required, achieved CCyR but has \>1 log increase in Bcr-Abl transcript levels~* Adequate end organ function~* Patients must have had an imatinib washout period of at least 3 days and not to exceed 7 days prior to the first dose of nilotinib. Group 1 patients must have been treated with imatinib for at least 1 year. There was no imatinib treatment duration requirement for Group 2 patients.~* For Group 1, patients were eligible for screening if they were treated with an imatinib dose of at least 400mg daily. Dose reduction could have occurred as long as the minimum dose was 300mg daily and the reduction lasted ≤ 28 days. The patient was required to be on 400 mg daily (or a higher dose) of imatinib for at least 6 consecutive months leading up to screening for this study.~* For Group 2 patients, dose reduction while on imatinib could have occurred as long as the minimum dose was 300 mg daily, and the reduction lasted ≤28 days.~Select Exclusion Criteria:~* Prior accelerated phase or blast crisis CML~* Patients achieving prior CCyR on imatinib who lost cytogenetic response prior to entering study~* Previously documented T315I mutations~* Prior therapy with any other tyrosine kinase inhibitor except imatinib~* Patients with contraindications to receiving nilotinib, including concomitant medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues